Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brazil launches massive leprosy hunt: can active screening catch hidden cases?

NCT ID NCT06761469

Knowledge-focused Sponsor: Hospital Alemão Oswaldo Cruz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This trial tests whether actively searching for leprosy cases in communities finds more people with the disease than waiting for them to come to clinics. Researchers will raise awareness, train healthcare workers, and use questionnaires and rapid tests in high-risk areas. About 1,925 people will take part across multiple municipalities in Brazil.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that active screening finds many hidden leprosy cases, helping reduce spread and improve early treatment.
What could go wrong
This is a pragmatic trial focused on detection, not a new treatment. Results may vary by location and may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

323 people

The number who actually took part.

Started

Jun 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (I) Municipalities * Municipality recognized by the Brazilian Institute of Geography and Statistics as part of the Brazilian Federation. * Municipality with operational epidemiological classification by the Ministry of Health (BMoH) as: 'municipalities with cases in the period from 2015 to 2019'. * Municipality with authorization/consent from the government to participate in the study. (II) Primary Health Units (Unidade Básica de Saúde or UBS) • UBS with territorial coverage (linked population) within the participating municipality. (III) Participants • Patients with positive Leprosy Suspicion Questionnaire (LSQ): children under five years old with Free and Informed Consent Form (ICF) signed by parents/guardians, 5-17 years old with ICF signed by parents/guardians and Free and Informed Assent Form (IAF) signed by the minor, and patients over 18 years old with ICF signed for: rapid test collection, comorbidity questionnaire and clinical evaluation; and if leprosy diagnosis is confirmed, collection of complementary exams. Exclusion Criteria: (I) Municipalities * Municipality with extreme population size (municipalities with a number of inhabitants lower than the 10th percentile and higher than the 90th percentile). * Municipality with operational epidemiological classification by the BMoH as: 'municipalities without cases in the period 2015 to 2019'. * Municipalities with active or recent participation (less than one year) in other active-finding strategies, in addition to the usual ones: ministerial, Non-Governmental Organizations (NGOs), academic, among others. (II) Primary Health Units * UBS with limited multidisciplinary team (absence of physicians, nurse and/or community health agents). * UBS with difficult access (no access by land, i.e. riverside populations). * UBS with territorial coverage exclusively of indigenous populations. (III) Participants * LSQ negative. * Patients with a previous diagnosis or history of treated leprosy. * Patients residing/registered outside the selected municipality.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leprosy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

leprosy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leprosy

Contacts and locations

Locations

  • Hospital Alemão Oswaldo Cruz

    São Paulo, São Paulo, 01327-001, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.